PRESIDE Trial: A Randomised Controlled Trial providing antidepressant medication information to patients with mild-to-severe depressive symptoms.
-
Trial Coordinator
Dr Sibel Saya,
+61 3 8559 7189
Project Details
The PRESIDE (PhaRmacogEnomicS In Depression) trial is a double-blind randomised controlled trial (RCT) of pharmacogenomically-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care. Participants who have depressive symptoms will be recruited to the study in their general practice by University of Melbourne researchers and provide a DNA sample.
Participants are randomly allocated to one of two groups and neither they, nor their GP are aware of which group they are in. One group will receive recommendations for which antidepressant drugs may be most effective for them based on how their DNA impacts how they break these drugs down. The other group will receive recommendations for antidepressant drugs based on current best practice. These reports are generated by the researchers and sent to participants' GPs. All participants, regardless of which group they are in, will decide with their GP which antidepressant, if any, is best for them.
This trial addresses significant knowledge gaps related to how clinically useful this type of pharmacogenomic test may be in managing patients with major depressive disorder in primary care. It will create evidence about the efficacy, safety, and cost-effectiveness of this approach, working with health service delivery partners and research end-users to ensure the findings can be implemented into practice as quickly as possible.
Researchers
Herman Prof Jon Emery, Academic GP, University of Melbourne
Dr. Sibel Saya, Study Coordinator/ Research Fellow, University of Melbourne
Prof. Jane Gunn, Academic GP, University of Melbourne
A/Prof. Chad Bousman, Research Psychiatrist, University of Melbourne
Prof. Graeme Suthers, Geneticist, Sonic Genetics
A/Prof. Victoria Palmer, Research Fellow, University of Melbourne
Prof. Catherine Mihalopoulos, Health Economist, Monash University
Prof. Timothy Chen, Research Fellow, University of Sydney
Dr. Thomas Polasek, Research Fellow, Flinders University
Dr. Patty Chondros, Statistician, University of Melbourne
Mr. Luke Spencer, Research Assistant, University of Melbourne
Ms. Rachel Brooks, Research Nurse, University of Melbourne
Ms. Jamie Jie Mei Liew, Research Support Officer, University of Melbourne
Mr. Raushaan Seychell, Research Assistant, University of Melbourne
Ms. Zoe Siviour, Research, Assistant, University of Melbourne
Ms. Georgia Ramsay, Research Assistant, University of Melbourne
Mr. Matthew Thoenig, Research Officer, University of Melbourne
Mr. Philip Ly, Research Assistant, University of Melbourne
Collaborators
Sonic Genetics (including Melbourne Pathology and Douglass Hanly Moir)
Translational Software
Funding
This study is funded by the Medical Research Future Fund.
Research Outcomes
This randomised controlled trial will provide evidence on the effectiveness and cost-effectiveness of using pharmacogenomic tests to tailor antidepressant prescribing.